Metastatic breast cancer: The Odyssey of personalization

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

(2017) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

(2016) J. Baselga et al.   CLINICAL CANCER RESEARCH

New Strategies in Breast Cancer: Immunotherapy

(2016) L. Pusztai et al.   CLINICAL CANCER RESEARCH

Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer

(2016) Gil Awada et al.   EXPERT OPINION ON EMERGING DRUGS

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer

(2016) Chee Khoon Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer

(2016) Ahmed Elsada et al.   LANCET ONCOLOGY

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

(2016) Nadia Harbeck et al.   LANCET ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

(2016) Serena Nik-Zainal et al.   NATURE

Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy

(2016) Thomas Schlange et al.   PHARMACOGENOMICS

The current use and attitudes towards tumor genome sequencing in breast cancer

(2016) I. Gingras et al.   Scientific Reports

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis

(2016) Won-Young Park et al.   Cancer Research and Treatment

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

(2015) J. Rodon et al.   ANNALS OF ONCOLOGY

14P * KEYNOTE-012: A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC)

(2015) L. Buisseret et al.   ANNALS OF ONCOLOGY

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

(2015) G. Gebhart et al.   ANNALS OF ONCOLOGY

RAD1901

(2015) Fiona Garner et al.   ANTI-CANCER DRUGS

The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients

(2015) R G Koleva-Kolarova et al.   BRITISH JOURNAL OF CANCER

Therapeutic targets of triple-negative breast cancer: a review

(2015) Vinayak S Jamdade et al.   BRITISH JOURNAL OF PHARMACOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

(2015) Kobe Reynders et al.   CANCER TREATMENT REVIEWS

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility

(2015) M. Ignatiadis et al.   CLINICAL CANCER RESEARCH

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

(2015) W. Hu et al.   CLINICAL CANCER RESEARCH

Crosstalk events in the estrogen signaling pathway may affect tamoxifen efficacy in breast cancer molecular subtypes

(2015) Guillermo de Anda-Jáuregui et al.   COMPUTATIONAL BIOLOGY AND CHEMISTRY

Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2015) Chau Dang et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

(2015) John R. Mackey et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

(2015) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

(2015) Edith A Perez et al.   LANCET ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

(2015) Christophe Le Tourneau et al.   LANCET ONCOLOGY

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Clinical management of breast cancer heterogeneity

(2015) Dimitrios Zardavas et al.   Nature Reviews Clinical Oncology

Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics

(2015) H. Gilbert Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

The biology of circulating tumor cells

(2015) K Pantel et al.   ONCOGENE

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience

(2015) M. J. McKee et al.   ONCOLOGIST

Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis

(2015) Q. Shen et al.   ONCOLOGIST

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

(2015) Murugan Kalimutho et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

(2015) Denise A. Yardley et al.   Trials

Triple negative breast cancer: looking for the missing link between biology and treatments

(2015) Giuseppe Palma et al.   Oncotarget

The biology and treatment of oligometastatic cancer

(2015) Diane K. Reyes et al.   Oncotarget

14q32-encoded microRNAs mediate an oligometastatic phenotype

(2015) Abhineet Uppal et al.   Oncotarget

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

(2014) F. Cardoso et al.   ANNALS OF ONCOLOGY

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?

(2014) M. Ignatiadis et al.   ANNALS OF ONCOLOGY

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

(2014) Debu Tripathy et al.   BMC CANCER

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

(2014) H J Lee et al.   BRITISH JOURNAL OF CANCER

The AURORA initiative for metastatic breast cancer

(2014) D Zardavas et al.   BRITISH JOURNAL OF CANCER

Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).:

(2014) José Baselga et al.   CANCER RESEARCH

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

Estrogen Receptor Mutations in Breast Cancer--New Focus on an Old Target

(2014) C. V. Segal et al.   CLINICAL CANCER RESEARCH

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Sharon H. Giordano et al.   JOURNAL OF CLINICAL ONCOLOGY

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives

(2014) Felipe Ades et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

(2014) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

(2014) Fabrice André et al.   LANCET ONCOLOGY

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

(2014) Joseph Gligorov et al.   LANCET ONCOLOGY

Editorial: Estrogen Receptor Mutations in Breast Cancer—An Anticipated “Rediscovery?”

(2014) Vincent Giguère   MOLECULAR ENDOCRINOLOGY

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

(2014) Daniel V.T. Catenacci   Molecular Oncology

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model

(2014) Olivier Trédan et al.   Targeted Oncology

Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer

(2014) Michel van Kruchten et al.   Cancer Discovery

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

(2013) D. W. Miles et al.   ANNALS OF ONCOLOGY

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

(2013) Flora Zagouri et al.   BREAST CANCER RESEARCH AND TREATMENT

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

(2013) D W Miles et al.   BRITISH JOURNAL OF CANCER

Predictive Biomarkers for Bevacizumab: Are We There Yet?

(2013) D. Maru et al.   CLINICAL CANCER RESEARCH

Liver resection for colorectal cancer metastases

(2013) S. Gallinger et al.   Current Oncology

High-levelERBB2gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting

(2013) Eva-Maria Fuchs et al.   INTERNATIONAL JOURNAL OF CANCER

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

(2013) G. Gebhart et al.   JOURNAL OF NUCLEAR MEDICINE

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

(2013) Stephen RD Johnston et al.   LANCET ONCOLOGY

Liquid biopsy: monitoring cancer-genetics in the blood

(2013) Emily Crowley et al.   Nature Reviews Clinical Oncology

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

(2012) M. Ignatiadis et al.   ANNALS OF ONCOLOGY

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

(2012) G Minuti et al.   BRITISH JOURNAL OF CANCER

A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women

(2012) Fatima Cardoso et al.   CANCER TREATMENT REVIEWS

FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

(2012) Otto Metzger-Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Oligometastatic cancer: an entity, a useful concept, or a therapeutic opportunity?

(2012) Tom Treasure   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

(2012) Thomas Bachelot et al.   LANCET ONCOLOGY

Stereotactic body radiotherapy for oligometastases

(2012) Alison C Tree et al.   LANCET ONCOLOGY

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

(2012) Rita S. Mehta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome

(2012) Daniel E. Abbott et al.   SURGERY

Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?

(2011) J. T. Ribeiro et al.   ANNALS OF ONCOLOGY

Tumor Metastasis: Molecular Insights and Evolving Paradigms

(2011) Scott Valastyan et al.   CELL

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study

(2011) C. K. Osborne et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Patterns of Distant Failure and Progression in Breast Cancer: Implications for the Treatment of Oligometastatic Disease

(2011) P.L. Dorn et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Projections of the Cost of Cancer Care in the United States: 2010-2020

(2011) A. B. Mariotto et al.   JNCI-Journal of the National Cancer Institute

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Oligometastases revisited

(2011) Ralph R. Weichselbaum et al.   Nature Reviews Clinical Oncology

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2-Positive Circulating Tumor Cells in Breast Cancer

(2011) Michail Ignatiadis et al.   PLoS One

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to Trastuzumab in Breast Cancer

(2009) P. R. Pohlmann et al.   CLINICAL CANCER RESEARCH

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

(2008) I. H. Park et al.   ANNALS OF ONCOLOGY

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

(2008) Giuseppe Gullo et al.   INVESTIGATIONAL NEW DRUGS

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY